Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001346824-25-000027
Filing Date
2025-10-27
Accepted
2025-10-27 16:07:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12648
2 JOINT FILING AGREEMENT ex-99-10272025_081043.htm EX-99.1 4569
  Complete submission text file 0001346824-25-000027.txt   18996
Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Subject) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94231 | Film No.: 251419954
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)